Quantitative informant- and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4

Gonzalo Sánchez-Benavides1,2,3 | Gemma Salvadó1,2 | Eider M. Arenaza-Urquijo1,2,3 | Oriol Grau-Rivera1,2,3,4 | Marc Suárez-Calvet1,2,3,4 | Marta Milà-Alomà1,2,3,5 | José María González-de-Echávarri1,2,3 | Carolina Minguillon1,2,3 | Marta Crous-Bou1,6,7 | Aida Niñerola-Balzán8 | Andrés Perissinotti8 | Juan Domingo Gispert1,2,5,9 | José Luis Molinuevo1,2,3,5 | for the ALFA Study1

1 Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
2 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
3 Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain
4 Servei de Neurología, Hospital del Mar, Barcelona, Spain
5 Universitat Pompeu Fabra, Barcelona, Spain
6 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
7 Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Hospital del Llobregat, Spain
8 Nuclear Medicine Department, Hospital Clínic, Barcelona, Spain
9 CIBER de Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain

Abstract

Introduction: Amyloid beta (Aβ) pathology is an Alzheimer’s disease early hallmark. Here we assess the value of longitudinal self- and informant reports of cognitive decline to predict Aβ positron emission tomography (PET) outcome in cognitively unimpaired middle-aged individuals.

Methods: A total of 261 participants from the ALFA+ study underwent [18F]flutemetamol PET and Subjective Cognitive Decline Questionnaire (SCD-Q) concurrently, and 3 years before scan. We used logistic regressions to evaluate the ability of SCD-Q scores (self and informant) to predict Aβ PET visual read, and repeated analysis of variance to assess whether changes in SCD-Q scores relate to Aβ status.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer’s Association
of Business and Knowledge of the Catalan Government, Grant/Award Number: 2017-SGR-892; the European Union’s Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie action; Instituto de Salud Carlos III, Grant/Award Number: PI19/00155; the Spanish Ministry of Science, Innovation, and Universities, Grant/Award Number: IJC2018-037478-I; the Spanish Ministry of Science and Innovation, Grant/Award Number: RYC-2013-13054; the Spanish Ministry of Science, Innovation, and Universities, Grant/Award Number: FJCI-2017-33437

1 | BACKGROUND

The conceptualization of Alzheimer’s disease (AD) has changed in the last decade thanks to the availability of methods to assess in vivo biomarkers, evolving from a clinical-pathological definition, in which definite diagnosis was achieved by post mortem analyses, to a biological one. This conceptual shift settled the definition of a preclinical stage of the disease, characterized by the presence of abnormal core AD biomarkers (amyloid beta \( \text{A} \beta \) and tau) in the absence of clinical expression. Mounting evidence suggests that brain pathologic changes, mainly \( \text{A} \beta \) deposition, begin decades before the emergence of the first symptoms, and this period offers a window of opportunity for testing preventive interventions targeting \( \text{A} \beta \). The establishment of these preventive studies and trials require the identification of individuals at a higher risk of developing AD in the near future. The standard way to measure \( \text{A} \beta \) pathology is through positron emission tomography (PET) imaging or cerebrospinal fluid (CSF) analysis. These techniques are, however, expensive and invasive. Therefore, an easier identification of individuals at higher risk of developing dementia (i.e., having positive AD biomarkers) is capital for a more efficient selection of candidates to participate in secondary prevention trials.

Although recent studies have explicitly sought predictors of brain amyloid pathology, they have mainly focused on symptomatic stages of the disease (i.e., mild cognitive impairment [MCI] and/or dementia). In these studies, the combination of predictors based on genetic (e.g., \text{APOE} \( \varepsilon4 \) status), demographic (e.g., age, sex), clinical, and cognitive data yielded the highest accuracy in predicting amyloid status. For example, Ba et al. recently reported an area under the curve (AUC) of 0.827 for positive \( \text{A} \beta \) PET prediction in MCI individuals from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database using \text{APOE} \( \varepsilon4 \) carrier status, age >60 years, and Alzheimer’s Disease Assessment Scale-Cognitive 13-item scale >13.5. However, studies in cognitively unimpaired individuals are scarce. A study published by Insel et al. in cognitively unimpaired ADNI individuals found similar results to those obtained in clinical samples: age, \text{APOE} \( \varepsilon4 \) status, baseline cognition, and cognitive decline after 24 months increased the predictive value for \( \text{A} \beta \) positivity by 60%.

An additional approach to improve the prediction of \( \text{A} \beta \) positivity in preclinical AD may be the use of subjective reports of cognitive decline. As pathology progresses through the preclinical stage, cognitive decline slowly emerges, remaining under the threshold of cognitive impairment as measured by standard neuropsychological tests. However, some individuals perceive changes in their cognitive ability. The self-perception of the subtle cognitive decline that occurs in absence of objective impairment is referred to as subjective cognitive decline (SCD). SCD is an established risk factor for future objective cognitive impairment and dementia and when accompanied by worries leads to seeking medical help. SCD is also associated with increased prevalence of AD core biomarkers positivity (\( \text{A} \beta \), t-tau, p-tau) and brain atrophy. Recently, Brunet et al. found that informant-based reporting of cognitive symptoms predicted amyloid positivity in a mixed sample of MCI and AD dementia patients. Similarily, but in this case in 86 ADNI clinically normal elders (mean age 78 years), Shokouhi et al. published a cross-sectional study showing that memory complaints primarily related to \( \text{A} \beta \) deposition whereas everyday planning complaints related to tau pathology. Despite these recent advances, AD biomarker prediction studies in younger samples assessing the value of change of subjective cognitive reports are still lacking. Furthermore, the longitudinal dynamics of SCD reports may be useful for such prediction, because reporting SCD consistently over time (assessed by means of a yes/no question about memory decline) has been related to increased incidence of dementia after 6 years.

This study aimed to assess the value of longitudinal self- and informant-reports of cognitive decline to predict \( \text{A} \beta \) PET outcome in cognitively unimpaired middle-aged individuals. We hypothesized that, beyond age and \text{APOE} \( \varepsilon4 \) status, both self- and informant-reports and their longitudinal change are valuable to predict \( \text{A} \beta \) status in cognitively unimpaired individuals.

2 | METHODS

2.1 | Participants

The first 261 consecutively recruited participants from the ongoing Alfa+ (Alzheimer and Families) study were included in the analyses. Alfa+ is a research cohort of middle-aged cognitively unimpaired (CU) subjects, many offspring of AD patients (169 out of 261, 64.8%, having at least one parent diagnosed with AD before age 75), which have been deeply characterized by clinical interviews, lifestyle questionnaires,
cognitive testing, CSF biomarkers, APOE genotyping, and neuroimaging (magnetic resonance imaging [MRI], and Aβ and fluorodeoxyglucose PET). All these procedures will be repeated every 3 years with the main aim of identifying the earliest pathophysiological changes in the preclinical AD continuum. In this study, data from the inclusion visit to the ALFA parent cohort performed between 2013 and 2014,24 which included clinical and neuropsychological data, and the available data from the first Alfa+ visit, performed between 2016 and 2018 (concurrent visit), which included Aβ PET studies in addition to cognitive and clinical data, were analyzed. Alfa+ inclusion criteria were: (1) subjects that have previously participated in the ALFA parent cohort,24 (2) age between 45 and 65 years at the moment of the inclusion in the parent cohort; (3) long-term commitment to the study: inclusion and follow-up visits and agreement to undergo at all tests and procedures (MRI, PET, and lumbar puncture). Alfa+ exclusion criteria included: (1) cognitive impairment (Clinical Dementia Rating [CDR]>0, Mini-Mental State Examination [MMSE]<27; semantic fluency <12), (2) any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol, (3) any contraindication to any test or procedure, or (4) family history of monogenic AD.

2.2 Self- and informant reports of cognitive decline

Perception of cognitive decline was measured with the participant (MyCog) and informant (TheirCog) versions of the Subjective Cognitive Decline Questionnaire (SCD-Q).25 The SCD-Q was devised to quantify perceived subjective cognitive decline over the last 2 years and inquiries about the presence or absence of difficulties in cognitive-related activities. It begins with three metacognitive questions: (1) Do you perceive memory or cognitive difficulties? (2) Would you ask a doctor about these difficulties? and (3) In the last 2 years, has your cognition or memory declined? These questions are followed by 24 items assessing perceived decline in cognitive activities of daily living that include memory, language, and executive tasks. Participants must answer if they believe to be performing these activities worse than roughly 2 years ago. Scores ranging from 0 to 24 are computed for both participant and informant reports, with higher scores indicating greater perceived cognitive decline. Subscores for memory (range 0–11), language (range 0–6), and executive (0–7) functions are also computed (see Rami et al.25 for details). The questionnaire was completed twice, at inclusion in the ALFA parent cohort and in the PET concurrent visit (first Alfa+ study visit), which on average was performed 3.2 years after (standard deviation [SD] = 0.7). The SCD-Q was self-completed at the beginning of the sessions, before any cognitive task was performed.

2.3 Neuropsychological assessment

A Preclinical Alzheimer Cognitive Composite-like (PACC-like) assessment was developed using the longitudinally available measures tapping episodic verbal memory, timed executive function, and semantic processing. Specifically, the PACC-like composite includes the total immediate score (total paired recall [TPR, 0–32]) and the total delayed free recall (TDFR, 0–32) from the Memory Binding Test (MBT), the Coding subtest from the Wechsler Adult Intelligence Scale (WAIS)-IV (0–135), and semantic fluency (animals in 1 minute). The PACC-like score was developed as described elsewhere.26 In brief, the four scores are standardized by dividing the difference between subject score and baseline mean by the baseline standard deviation and then summed to obtain the composite. The Goldberg Anxiety and Depression Scale (GADS) and Hospital Anxiety and Depression Scale (HADS) were used to measure anxiety and depressive symptoms at inclusion and PET concurrent visit, respectively. Participants did not receive any feedback regarding their performance at the neuropsychological assessment.

2.4 Aβ PET: acquisition and analysis

Participants underwent [18F]flutemetamol PET scan coincident (mean interval 4.6±3 months) with the second SCD-Q and cognitive assessment (PET concurrent visit). Imaging was conducted in a Siemens Biograph mCT, after a cranial computed tomography (CT) scan for attenuation correction. Participants were injected with 185 MBq of [18F]flutemetamol, and 4 frames of 5 minutes each were acquired 90 minutes post-injection. A nuclear medicine physician visually rated the scans as positive (Aβ+) or negative (Aβ−) using standard clinical criteria as specified in the Summary of Product Characteristics (SmPC; https://www.ema.europa.eu/en/documents/product-information/vizamyl-epar-product-information_en.pdf) of the tracer.
In addition to the visual assessment, PET images were also quantified to obtain a measure of $A\beta$ accumulation in the brain. PET processing was performed following the standard Centiloid pipeline using SPM12. In brief, PET images are first coregistered to their respective T1-weighted images and, afterward, moved to Montreal Neurological Institute space using the normalization transformation derived from the segmentation of the T1-weighted image. PET images were intensity normalized using whole cerebellum as a reference region. Centiloid values were calculated from the mean values of the standard Centiloid target region (http://www.gain.org/centiloid-project) using the transformation previously calibrated. Participants agreed to not receive any information about their amyloid and APOE status.

### 2.5 | Statistical analyses

#### 2.5.1 | Descriptive analysis

Data were described using means and standard deviations for continuous variables and percentages for categorical ones. We compared $A\beta^+$ and $A\beta^-$ groups for sociodemographic characteristics and clinical data by means of t-tests and Chi-square tests as appropriate.

#### 2.5.2 | Predictive analysis of $A\beta$ status

The ability of SCD-Q scores to predict positive amyloid status was assessed by means of logistic regressions, adjusting for age, sex, time between PET acquisition and SCD-Q, and APOE $\epsilon 4$ carriership status. SCD-Q Total Scores as well as subscores (Memory, Language, and Executive) for both the MyCog and TheirCog were analyzed. Prospective prediction, using data from the inclusion visit, and concurrent prediction, using data from the PET concurrent visit, were explored. Secondarily, for the most significant predictors, the classification performance of several cut-offs were also tested with logistic regressions using binarized SCD-Q variables as categorical independent variables. The ability of the cognitive composite (PACC-like) to predict amyloid outcomes was also assessed by means of a logistic regression, including education as an additional covariate. Main predictive analyses (i.e., SCD-Q prediction of $A\beta$ PET outcome) were also carried out without introducing APOE $\epsilon 4$ as a covariate to assess the prediction ability blind to APOE genotype, and also after stratifying the sample by APOE $\epsilon 4$ status.

We also explored the capacity of the change in SCD-Q measures to predict $A\beta$ PET positivity. For this aim, a set of repeated measures analyses of variance (ANOVAs) was used to explore differences in the mean change of SCD-Q scores between $A\beta^+$ and $A\beta^-$ groups (group x time interaction). Age, sex, APOE $\epsilon 4$ status and interval time between visits were included in all the models. Additionally, differences in the cognitive composite PACC-like change between $A\beta^+$ groups were also tested. Education was included as a covariate in these models. Interactions among predictors were also tested and kept in final models when significant.

In secondary analyses, general linear models were constructed to assess the SCD-Q scores ability to predict continuous Centiloid $A\beta$ measures, adjusted by age, sex, and APOE $\epsilon 4$ status.

### 3 | RESULTS

#### 3.1 | Characteristics of the sample

The scans of 33 out of 261 participants (12.6%) were classified as $A\beta$ positive in PET visual read. Table 1 shows descriptive sociodemographic, clinical, and basic inclusion data by $A\beta$ status. Participants with positive scans were older than those with negative ones and were more frequently APOE $\epsilon 4$ carriers. There were no differences in the mean interval between inclusion and PET concurrent visits between groups; 70.1% of the informants did not change between visits. No difference in percentage of change of the informants was observed between $A\beta^+$ and $A\beta^-$ groups (28.3% vs 31.3% chi-square $P = .4$).

#### 3.2 | Prospective and concurrent prediction of $A\beta$ status with SCD-Q and cognitive scores

Table 2 and Figure 1 show the results of the logistic regression for $A\beta$ status prediction using SCD-Q scores. Self-reports at inclusion (MyCog) did not predict $A\beta$ status 3 years after. Only memory subscores showed a trend to significant prediction (odds ratio [OR] = 1.175; $P = .057$), that became significant at PET concurrent visit (OR = 1.221; $P = .022$). Regarding informant reports (TheirCog), they displayed a similar pattern in memory subscores, that is a trend for prospective prediction (OR = 1.114; $P = .055$) and a significant prediction at PET concurrent visit (OR = 1.291; $P = .039$), and, for total
score and executive subscore, they predicted $A\beta$ status both prospectively and concurrently.

We also tested the classification ability of all the possible cut-offs of PET-concurrent MyCog memory and TheirCog executive subscores (which were the measures that displayed the highest ORs) using logistic regression with covariates. The cut-off that yielded best results was two in both cases. Thus, endorsing two or more out of the 11 memory items displayed an OR of 2.88 (confidence interval [CI] 95% = 1.26-6.57; $P = .012$; sensitivity = 0.61; specificity = 0.65), and endorsing two out of the seven executive ones achieved an OR of 2.79 (CI 95% = 1.12-6.92; $P = .027$; sensitivity = 0.30; specificity = 0.83). Similarly, for the inclusion SCD-Q MyCog memory subscore we found that endorsing three or more items prospectively predicted $A\beta$ status (OR = 2.6; CI 95% = 1.15-6.17; $P = .022$; sensitivity = 0.49; specificity = 0.70).

Predictive analyses without including $APOE\varepsilon4$ as a covariate yielded similar results to those obtained when including it (see Table S1 in supporting information). Further analyses after stratification of the sample by $APOE\varepsilon4$ status showed that prediction with the SCD-Q was mainly observed in the non-carriers (see Tables S2 and S3 in supporting information).

The results from logistic regressions using cognitive performance as predictor of $A\beta$ status did not show significant results for the PACC (prospective: OR = 1.006, 95% CI = 0.851-1.189; $P = .948$; PET concurrent: OR = 0.994, 95% CI = 0.791-1.127, $P = .523$), or for the specific tests used to calculate it (all $P > .4$, data not shown).

### 3.3 | Prediction of amyloid positivity with longitudinal change of SCD-Q and cognition

We observed a global trend in which participants from the $A\beta$- group tended to reduce SCD-Q scores at their PET-concurrent visit compared to the inclusion one, while $A\beta+$ tended to maintain them (see Table 3 descriptive data). However, the difference in the change between groups in ANOVA for repeated measures was only significant in the MyCog executive subscore. While this score decreased in $A\beta$- individuals, it increased in $A\beta+$. In this model, we also found an interaction with sex ($P = .022$) and further analyses performed separately in women and men revealed that the effect was driven by females ($P = .003$; males $P = .435$). No differences in longitudinal change were observed for TheirCog scores or for cognitive variables.

### 3.4 | Association between quantitative $A\beta$ measures and SCD-Q and cognition

Independent general linear models with Centiloid values as dependent variable and SCD-Q scores as predictors, with age, sex, and $APOE\varepsilon4$ as covariates, revealed significant associations between TheirCog executive subscore at inclusion and the observed $A\beta$ load 3 years later ($B = 1.92; P = .039$; partial eta$^2 = 0.017$), and a trend to significance at PET-concurrent assessment ($B = 2.07; P = .067$; partial eta$^2 = 0.013$). No association was observed between Centiloids and cognitive performance as measured by the PACC-like composite at any time point.

### 4 | DISCUSSION

This study explored the ability of participant and informant quantitative reports of cognitive changes to predict $A\beta$ PET positivity in cognitively unimpaired participants at risk for AD. The main results show that self-perception of decline in memory increases the probability of having a positive $A\beta$ PET scan and that informant perception of executive decline is even more useful to predict $A\beta$ status. Furthermore, informant reports predicted $A\beta$ PET outcome not only concurrently,
but also prospectively 3 years before the scan. We also observed that the longitudinal increase of self-reported executive decline is predictive of Aβ deposition, but only in women. Notably, objective cognitive performance failed to predict Aβ status in this study.

By using a validated questionnaire to assess SCD, the SCD-Q, we observed that cross-sectional scores and longitudinal change have value to predict Aβ PET status by visual read, which is the common measure of amyloidosis in clinical settings and the inclusion criterion in most clinical trials, independently of age and APOE ε4 status. In our sample, we found that memory subscores from both self- and informant-reports were useful to predict PET outcome concurrently, and informant reported executive subscores were also predictive concurrently and even prospectively using information collected 3 years before the scan. Globally, our results on the association between PET-concurrent SCD-Q and Aβ are in line with previous studies that found a moderate association between the intensity of subjective complaints and amyloid-PET measures in cognitively unimpaired subjects.29–34

The use of a quantitative measure using a validated SCD questionnaire allowed us to find these associations. Indeed, the binary variable presence/absence of SCD, defined by the answers to the first initial question of the SCD-Q “Do you perceive memory or cognitive difficulties?” was not able to predict PET outcome at inclusion or at PET-concurrent visit (P = .9, P = .15, data not shown).

The observed pattern, in which informant scores displayed higher and earlier ability to predict Aβ status than self-reports, gives support to the longitudinal studies that found a superior value of informant reports in predicting future cognitive decline in cognitively unimpaired elders.35–40 However, their value in predicting biomarker status in unimpaired subjects is far less explored and yielded mixed results. A study in the ADNI cohort showed that informant reports were more strongly associated to amyloid PET standard uptake value ratio than self-reports, when the global sample, including cognitively unimpaired, MCI, and AD dementia participants, was analyzed. However, within-group analysis revealed that the relationship was significant only in MCI participants.41 Likewise, a recent study in the SCIENCE cohort showed that informant reports of decline did not significantly predict preclinical AD,42 but our results cannot be directly compared to these. The SCIENCE cohort are exclusively composed of subjects with SCD recruited from a memory clinic setting, and they used a dichotomized variable for positive/negative complaint instead of analyzing it as a continuous variable. Study setting, in which participants are worried enough to seek medical advice, and the cut-off used to define positive complaint, may explain the divergence of results. On the other hand, we identified two reports that are in line with our findings. Using the same questionnaire as we used, Valech et al.,43 found that TheirCog scores, but not MyCog ones, significantly differed between controls and preclinical AD (defined by Aβ42 levels in CSF), with a significant AUC of 0.75 for discriminating between them. Similarly, Cacciamani et al.,44 by means of a subject-informant discrepancy index approach, found that amyloid burden was more frequent (47%) in the low-awareness group (informant >subject perception of decline) than in the highly aware group (24%). In their study, they argue that low awareness may represent a very early form of anosognosia and, as such, might serve as a specific indicator of AD pathology.

We found that endorsement of at least 2 out of the 11 items in the memory subscore of the MyCog, or 2 out of 7 items in the executive one of the TheirCog scale almost tripled the chance of being classified as Aβ positive. However, we observed a different classification pattern between self- and informant reports. While sensitivity and specificity of the self-reported memory cut-off was more balanced (both above 60%), the informant reported executive cut-off enhanced specificity (83%) over sensitivity (30%). Thus, absence of informant perception of decline in executive items was highly associated to a negative Aβ PET visual read, but presence of perception of decline in these items does not necessarily indicate a positive Aβ PET scan. This fact may be related in many cases to other non-AD changes, such as physiological aging. It is noteworthy that the range of OR of the cut-offs in predicting amyloidosis are similar to the effect of being an APOE ε4 carrier observed in our sample (OR = 3.1 P = .005 adjusted for age and sex), and in general population at 70 years old (OR≈3),34,45,46 but less than the reported effect of the combination of being APOE ε4 carrier and classified as having SCD (OR≈7), and far from the effect of

FIGURE 1  Odds ratios (ORs) with 95% confidence intervals (CIs) for positive amyloid beta scan prediction using Subjective Cognitive Decline Questionnaire (SCD-Q) scores. Models were adjusted by age, sex, and APOE ε4 status.
homozgyosity (OR≈18). Indeed, we showed that informant report predictive ability is independent from the effect of APOE ε4, because we have included it as a covariate in main models. When APOE ε4 status was excluded from the models the associations were weaker but still significant. Interestingly, in a stratified analysis by APOE ε4 status we observed that Aβ PET outcome was mainly predicted by SCD-Q in non-carriers. This fact suggest that SCD reports may be able to capture amyloid-related subtle cognitive changes that are independent of APOE ε4. The weight of APOE ε4 in predicting amyloidioidosis is so strong that SCD reports do not add significant predictive value in ε4 allele carriers. Our results, rather than going against the view of APOE ε4 being an SCD-plus feature, highlight the relevance of SCD reports in predicting amyloidosis when the main biological driver is absent.

We also explored, retrospectively, the longitudinal change in SCD-Q scores. Globally, we observed a trend showing that decreases in scores related to Aβ- status. In contrast, the Aβ+ group tended to maintain, and in some cases increase, the scores, reflecting a higher degree of subjective complaint. Some longitudinal evidence pointed out that stability, or persistence, of SCD through time increased the degree of subjective complaint. Some longitudinal evidence pointed out that stability, or persistence, of SCD through time increased the degree of subjective complaint. 

tab 3

|                      | Aβ-  | Aβ+  | Aβ-  | Aβ+  | Group x Time |
|----------------------|------|------|------|------|--------------|
| Inclusion visit      |      |      |      |      |              |
| PACC M(SD)           | 0.21 (2.72) | -0.64 (2.53) | 0.55 (2.88) | -0.99 (0.62) | .574         |
| MBT-TDFR M(SD)       | 17.3 (5.1) | 17.0 (4.9) | 17.9 (5.3) | 16.3 (3.9) | .550         |
| MBT- TPR M(SD)       | 24.3 (4.1) | 24.7 (3.8) | 25.4 (4.1) | 23.7 (3.2) | .106         |
| Coding WAIS IV M(SD) | 67.5 (14.2) | 60.5 (15.4) | 67.2 (14.0) | 58.7 (15.7) | .254         |
| Semantic fluency M(SD) | 23.1 (5.1) | 21.1 (4.1) | 23.2 (5.1) | 21.6 (4.9) | .630         |
| SCD-MyCog            |      |      |      |      |              |
| Total score M(SD)    | 5.02 (4.99) | 5.73 (3.87) | 3.85 (4.31) | 5.88 (3.97) | .175         |
| Memory subscore M(SD)| 2.03 (2.42) | 2.67 (2.35) | 1.39 (2.00) | 2.51 (2.40) | .533         |
| Language subscore M(SD)| 1.75 (1.78) | 1.97 (1.67) | 1.56 (1.60) | 2.00 (1.32) | .464         |
| Executive subscore M(SD)| 1.25 (1.47) | 1.09 (1.10) | 0.91 (1.30) | 1.28 (1.02) | .029         |
| SCD-Q TheirCog       |      |      |      |      |              |
| Total score M(SD)    | 2.22 (3.18) | 3.33 (3.92) | 1.57 (2.71) | 2.76 (3.11) | .801         |
| Memory subscore M(SD)| 0.99 (1.54) | 1.48 (2.03) | 0.70 (1.36) | 1.33 (1.70) | .773         |
| Language subscore M(SD)| 0.66 (1.14) | 0.85 (1.20) | 0.48 (0.96) | 0.82 (1.16) | .794         |
| Executive subscore M(SD)| 0.57 (1.02) | 1.00 (1.99) | 0.39 (0.86) | 0.61 (0.99) | .533         |

Note: Group x Time interaction adjusted by age, sex, and time between visits. Education was also included as covariate in cognitive variables. Abbreviations: Aβ, amyloid beta; ANOVA, analysis of variance, APOE, APOLIPOPROTEIN E; MBT, Memory Binding Test; PACC, Preclinical Alzheimer's Cognitive Composite; SCD-Q, Subjective Cognitive Decline Questionnaire; MyCog, Participant scores; PET, positron emission tomography; SD, standard deviation; TDFR, Total Delayed Free Recall; TheirCog, Informant scores; TPR, Total Paired Recall; WAIS, Wechsler Adult Intelligence Scale.

When longitudinal change was formally tested in our study by means repeated ANOVA adjusting for age, sex, interval between visits, and APOE ε4 status, Aβ groups only differ in the change of the self-reported executive subscore, that decreases in the Aβ– group and increases in the Aβ+ one. Since a significant interaction with sex was found in this analysis, we reran it separately in men and women and observed that the effect was driven exclusively by the latter. In line with our finding, it has been recently suggested that reporting SCD may be a stronger predictor of incident dementia in women than in men. Although in this study the authors explored only memory complaints, it may be possible that subtle increments in perceived difficulties in other domains, such as executive function, may be noticed more by Aβ+ women, because women seem to outperform men in perceiving subtle pathological changes.

Although memory is the commonly studied domain in preclinical AD, mounting evidence has shown that cognitively unimpaired Aβ+ subjects display lower performance not only in memory but also in executive function compared to Aβ– ones (see Baker et al. for a review). In our study, we have not found differences in cognitive outcomes. Nevertheless, the results in informant reports suggest that a close relative may be able to notice a subtle attentional/executive decline related to amyloid deposition, even before this is apparent in neuropsychological group analysis. This subtle decline would be exressed in challenging, highly demanding tasks in daily living, such as planning complex activities or dual tasking.

Our study is not free of limitations. The main one is having available only a PET scan performed at follow-up visit. We do not know the
participants’ amyloid status at inclusion and, therefore, we cannot assess whether an increase in SCD-Q scores relates to an increase in amyloid deposition. However, further scans and cognitive follow-up visits are underway and will eventually permit further analyses. Another caveat relates to the limited information available for informants. Their mood, knowledge, and fears about AD may well affect the assessment of participants’ cognitive status.

In summary, we found that both self- and informant reports of cognitive decline in cognitively unimpaired subjects are useful to predict Aβ positive status assessed by amyloid PET independently of age and APOE ε4 status. Informant reports of change in executive items showed the higher predictive value, followed by self-reports of memory decline. In longitudinal reports, women that increase their executive complaints over time are more likely to have a positive amyloid PET.

ACKNOWLEDGMENTS

This publication is part of the ALFA study (Alzheimer’s and Families). The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. Collaborators of the ALFA study are: Annabella Beteta, Raffaele Cacciaglia, Alba Cañas, Carme Deulofeu, Irene Cumplido, Ruth Dominguez, Maria Emilio, Carles Falcon, Karine Fauria, Sherezade Fuentes, Laura Hernandez, Gema Huesa, Jordi Huguet, Paula Marne, Tania Menchón, Grégory Operto, Albina Polo, Sandra Pradas, Aílex Sala-Vila, Gonzalo Sánchez-Benavides, Gemma Salvadó, Anna Soteras, Marc Vilanova, and Natalia Vilor-Tejedor.

The authors would like to thank GE Healthcare for kindly providing [18F]flutemetamol doses for ALFA+ participants.

The ALFA+ study was approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona, and registered at Clinicaltrials.gov (Identifier: NCT02485730). All participants signed the study’s informed consent form that had also been approved by the Independent Ethics Committee “Parc de Salut Mar,” Barcelona.

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

CONFLICTS OF INTEREST

José Luis Molinuevo has served/serves as a consultant or on advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences. Juan Domingo Gispert has given lectures in symposia sponsored by the following for-profit companies: General Electric, Philips, and Biogen. The remaining authors declare that they have no conflicts of interest.

FUNDING INFORMATION

The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. Marc Suárez-Calvet received funding from the European Union’s Horizon 2020 Research and Innovation Program under the Marie Sklodowska-Curie action grant agreement No 752310, and currently receives funding from Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation, and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). Juan Domingo Gispert is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). Oriol Grau-Rivera is supported by the Spanish Ministry of Science, Innovation, and Universities (FJCI-2017-33437). ASV is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029). Eider M. Arenaza-Urquijo is supported by the Spanish Ministry of Science, Innovation and Universities–Spanish State Research Agency (RYC2018-026053-I). Carolina Minguillon was supported by the Spanish Ministry of Economy and Competitiveness (grant no. IEDI-2016-00690).

REFERENCES

1. Molinuevo JL, Minguillon C, Rami L, Gispert JD. The rationale behind the new Alzheimer’s disease conceptualization: lessons learned during the last decades. J Alzheimer’s Dis. 2018;62:1067-1077.
2. Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292-323.
3. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535-562.
4. Bateman RJ, Fagan AM, Holtzman DM, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795-804.
5. Golde T, Bonte BT, Gałasko D. Alzheimer’s disease: the right drug, the right time. Science. 2018;362:1250-1252.
6. Brunet HE, Miller JB, Shi J, Chung B, Munter BT, Sabbagh MN. Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography? Alzheimer’s Dement. 2019;11:424-429.
7. Ba M, Ng KP, Gao X, Kong M, Guan L, Yu L. The combination of apolipoprotein E4, age and Alzheimer’s Disease Assessment Scale – Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Eur J Neurol. 2019;26:733-e53.
8. Lee JH, Byun MS, Yi D, et al. Prediction of cerebral amyloid with common information obtained from memory clinic practice. Front Aging Neurosci. 2018;10:1-8.
9. Koppala A, Wolfrubin S, Kleinidam L, et al. The latent dementia phenotype δ is associated with cerebrospinal fluid biomarkers of Alzheimer’s disease and predicts conversion to dementia in subjects with mild cognitive impairment. J Alzheimer’s Dis. 2016;49:547-560.
10. Kreis W, Jin P, Lee S, et al. Odor identification ability predicts PET amyloid status and memory decline in older adults. J Alzheimer’s Dis. 2018;62:1759-1766.
11. Carr SJ, Jaeger J, Bian S, et al. Associating cognition with amyloid status using partially ordered set analysis. Front Neurol. 2019;10:1-15.
12. Insel PS, Palmqvist S, Mackin RS, et al. Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2016;4:76-84.
13. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s Dement. 2014;10:844-852.

14. Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol. 2017;13:369-396.

15. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130:439-451.

16. Eckerström M, Göthlin M, Rolstad S, et al. Longitudinal evaluation of subjective cognitive decline and preclinical Alzheimer’s disease in a memory clinic sample. Alzheimer’s Dement Diagnosis. Assess Dis Moit. 2017;8:96-107.

17. Snitz BE, Wang T, Cloonan YK, et al. Risk of progression from subjective cognitive decline to mild cognitive impairment: the role of study setting. Alzheimers Dement. 2018;14:734-742.

18. Ramakers IHGB, Visser PJ, Bittermann AJN, Ponds RWHM, van Boxtel MPJ, Verhey FRJ. Characteristics of help-seeking behaviour in subjects with subjective memory complaints at a memory clinic: a case-control study. Int J Geriatr Psychiatry. 2009;24:190-196.

19. Wolfsgruber S, Molinuevo JL, Wagner M, et al. Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimers Res Ther. 2019;11(1):8.

20. Perrotin A, de Flores R, Lamberton F, et al. Hippocampal subfield volumetry and 3D surface mapping in subjective cognitive decline. J Alzheimers Dis. 2015;48(Suppl 1):S141-S150.

21. Hu X, Teunissen C, Spottke A, et al. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer’s disease—Data from three memory clinic studies. Alzheimers Dement. 2018;49:1-9.

22. Shokouhi S, Conley AC, Baker SL, et al. The relationship between domain-specific subjective cognitive decline and Alzheimer’s pathology in normal elderly adults. Neurobiol Aging. 2019;81:22-29.

23. Wolfsgruber S, Kleineidam L, Wagner M, et al. Differential risk of incident Alzheimer’s disease dementia in stable versus unstable patterns of subjective cognitive decline. J Alzheimers Dis. 2016;54:1135-1146.

24. Molinuevo JL, Gramunt N, Gispert JD, et al. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2016;2:82-92.

25. Rami L, Mollica MA, Garca-Sanchez C, et al. The subjective cognitive decline questionnaire (SCD-Q): a validation study. J Alzheimers Dis. 2014;44:453-466.

26. Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961-970.

27. Klunk WE, Koeppke RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s Dement. 2015;11:1-15.e4.

28. Salvado G, Molinuevo JL, Brugulat-Serrat A, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27.

29. Amariglio RE, Mormino EC, Pietras AC, et al. Subjective cognitive concerns, amyloid-b, and neurodegeneration in clinically normal elderly. Neurology. 2015;85:56-62.

30. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50:2880-2886.

31. Buckley RF, Hanseebu B, Schultz AP, et al. Region-Specific association of subjective cognitive decline with tauopathy independent of global β-Amyloid Burden. JAMA Neurol. 2017;74:1435.

32. La Joie R, Perrotin A, Egret S, et al. Qualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders: association with medical help seeking, cognitive deficits, and β-amyloid imaging. Alzheimer’s Dement (Amsterdam, Netherlands). 2016;5:23-34.

33. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012;69:223-229.

34. Mielke MM, Wiste HJ, Weigand SD, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology. 2012;79:1570-1577.

35. Carr DB, Gray S, Baty J, Morris JC. The value of informant versus individual’s complaints of memory impairment in early dementia. Neurology. 2000;55:1724-1726.

36. Rabin LA, Wang C, Katz MJ, Derby CA, Buschke H, Lipton RB. Predicting Alzheimer’s disease: neuropsychological tests, self-reports, and informant reports of cognitive difficulties. J Am Geriatr Soc. 2012;60:1128-1134.

37. Gifford KA, Liu D, Carmona H, et al. Inclusion of an informant yields strong associations between cognitive complaint and longitudinal cognitive outcomes in non-demented elders. J Alzheimers Dis. 2015;43:121-132.

38. Slavin MJ, Sachdev PS, Kochan NA, et al. Predicting cognitive, functional, and diagnostic change over 4 years using baseline subjective cognitive complaints in the Sydney Memory and Ageing Study. Am J Geriatr Psychiatry. 2015;23:906-914.

39. Gavett R, Dunn JE, Stoddard A, Harty B, Weintraub S. The Cognitive Change in Women study (CCW): informant ratings of cognitive change but not self-ratings are associated with neuropsychological performance over 3 years. Alzheimers Dis Assoc Disord. 2011;25:305-311.

40. Caselli RJ, Chen K, Locke DEC, et al. Subjective cognitive decline: self and informant comparisons. Alzheimer’s Dement. 2014;10:93-98.

41. Rueda AD, Lau KM, Saito N, et al. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer’s disease. Alzheimer’s Dement. 2015;11:1080-1089.

42. Slot RER, Sikkes SAM, Berkhof J, et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimers Dement. 2019;15:465-476.

43. Valech N, Mollica MA, Olives J, et al. Informant’s perception of subjective cognitive decline helps to discriminate preclinical Alzheimer’s disease from normal aging. J Alzheimers Dis. 2015;48:587-598.

44. Cacciamani F, Fadet S, Gagliardi G, et al. Low Cognitive awareness, everyday function in comparison to objective markers of Alzheimer’s disease. Alzheimer’s Dement Diagnosis. 2018;14:380-387.

45. Rabin LA, Wang C, Katz MJ, Derby CA, Buschke H, Lipton RB. Predicting Alzheimer’s disease: neuropsychological tests, self-reports, and informant reports of cognitive difficulties. J Am Geriatr Soc. 2012;60:1128-1134.

46. Gifford KA, Liu D, Carmona H, et al. Inclusion of an informant yields strong associations between cognitive complaint and longitudinal cognitive outcomes in non-demented elders. J Alzheimers Dis. 2015;43:121-132.

47. Slavin MJ, Sachdev PS, Kochan NA, et al. Predicting cognitive, functional, and diagnostic change over 4 years using baseline subjective cognitive complaints in the Sydney Memory and Ageing Study. Am J Geriatr Psychiatry. 2015;23:906-914.

48. Gavett R, Dunn JE, Stoddard A, Harty B, Weintraub S. The Cognitive Change in Women study (CCW): informant ratings of cognitive change but not self-ratings are associated with neuropsychological performance over 3 years. Alzheimers Dis Assoc Disord. 2011;25:305-311.

49. Caselli RJ, Chen K, Locke DEC, et al. Subjective cognitive decline: self and informant comparisons. Alzheimer’s Dement. 2014;10:93-98.

50. Rueda AD, Lau KM, Saito N, et al. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer’s disease. Alzheimer’s Dement. 2015;11:1080-1089.
51. Baker JE, Lim YY, Pietrzak RH, et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: a meta-analysis. Alzheimer’s Dement Diagnosis. Assess Dis Monit. 2017;6:108-121.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.